Celgene's most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $150.00 short put and a strike $140.00 long put offers a potential 11.23% return on risk over the next 19 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $150.00 by expiration. The full premium credit of $1.01 would be kept by the premium seller. The risk of $8.99 would be incurred if the stock dropped below the $140.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.
The RSI indicator is at 61.21 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
3 Reasons Celgene Is a Buy
Mon, 02 Jun 2014 22:31:57 GMT
1:52 am Celgene presents post-hoc analysis of overall survival in Phase III MPACT study of patients with advanced pancreatic cancer
Mon, 02 Jun 2014 05:52:00 GMT
Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014
Sun, 01 Jun 2014 13:00:00 GMT
Business Wire – Celgene Corporation today announced updated Overall Survival results from a post-hoc analysis of its phase III MPACT study of ABRAXANE® in combination with gemcitabine in treatment-naïve patients with metastatic pancreatic cancer.
Celgene: Why There's Upside
Fri, 30 May 2014 18:14:00 GMT
Scorned Pfizer Should Forget AstraZeneca and Buy Celgene Instead
Thu, 29 May 2014 22:32:25 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook